Kindred Biosciences (KIN) Misses Q4 EPS by 2c

Kindred Biosciences (NASDAQ: KIN) reported Q4 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.26 million.

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Benchmark Reiterates Buy Rating on Malibu Boats (MBUU) on Significant Earnings Upside
• AiRWA receives Nasdaq deficiency notice over late 10-K filing